Novo Nordisk As Stock Performance
| NONOF Stock | USD 126.26 3.76 3.07% |
On a scale of 0 to 100, Novo Nordisk holds a performance score of 10. The company secures a Beta (Market Risk) of 0.47, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Novo Nordisk's returns are expected to increase less than the market. However, during the bear market, the loss of holding Novo Nordisk is expected to be smaller as well. Please check Novo Nordisk's skewness, and the relationship between the potential upside and rate of daily change , to make a quick decision on whether Novo Nordisk's current price movements will revert.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Novo Nordisk AS are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Novo Nordisk reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 10.7 B |
Novo |
Novo Nordisk Relative Risk vs. Return Landscape
If you would invest 10,490 in Novo Nordisk AS on January 24, 2024 and sell it today you would earn a total of 2,136 from holding Novo Nordisk AS or generate 20.36% return on investment over 90 days. Novo Nordisk AS is currently producing 0.3252% returns and takes up 2.3161% volatility of returns over 90 trading days. Put another way, 20% of traded pink sheets are less volatile than Novo, and 94% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Novo Nordisk Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novo Nordisk's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Novo Nordisk AS, and traders can use it to determine the average amount a Novo Nordisk's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1404
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NONOF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.32 actual daily | 20 80% of assets are more volatile |
Expected Return
| 0.33 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average Novo Nordisk is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novo Nordisk by adding it to a well-diversified portfolio.
Novo Nordisk Fundamentals Growth
Novo Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Novo Nordisk, and Novo Nordisk fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novo Pink Sheet performance.
| Return On Equity | 0.72 | |||
| Return On Asset | 0.22 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.43 % | |||
| Current Valuation | 292.82 B | |||
| Shares Outstanding | 1.72 B | |||
| Price To Earning | 41.24 X | |||
| Price To Book | 26.64 X | |||
| Price To Sales | 1.73 X | |||
| Revenue | 176.95 B | |||
| EBITDA | 76.8 B | |||
| Cash And Equivalents | 31.04 B | |||
| Cash Per Share | 13.68 X | |||
| Total Debt | 20.77 B | |||
| Debt To Equity | 0.34 % | |||
| Book Value Per Share | 37.10 X | |||
| Cash Flow From Operations | 78.89 B | |||
| Earnings Per Share | 3.53 X | |||
| Total Asset | 241.26 B | |||
| Retained Earnings | 41.06 B | |||
| Current Asset | 51.58 B | |||
| Current Liabilities | 41.59 B | |||
About Novo Nordisk Performance
To evaluate Novo Nordisk AS Pink Sheet as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Novo Nordisk generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Novo Pink Sheet's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Novo Nordisk AS market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Novo's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. NOVO NORDISK is traded on OTC Exchange in the United States.Things to note about Novo Nordisk AS performance evaluation
Checking the ongoing alerts about Novo Nordisk for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Novo Nordisk AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company has accumulated 20.77 B in total debt with debt to equity ratio (D/E) of 0.34, which is about average as compared to similar companies. Novo Nordisk AS has a current ratio of 0.92, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Novo Nordisk until it has trouble settling it off, either with new capital or with free cash flow. So, Novo Nordisk's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novo Nordisk AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novo to invest in growth at high rates of return. When we think about Novo Nordisk's use of debt, we should always consider it together with cash and equity. |
- Analyzing Novo Nordisk's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novo Nordisk's stock is overvalued or undervalued compared to its peers.
- Examining Novo Nordisk's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novo Nordisk's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novo Nordisk's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novo Nordisk's pink sheet. These opinions can provide insight into Novo Nordisk's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Novo Pink Sheet analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |